Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT06097728
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 304
- Registration Number
- NCT06096844
- Locations
- 🇺🇸
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
🇺🇸Highlands Oncology Group - Rogers, Rogers, Arkansas, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- AbbVie
- Registration Number
- NCT06093503
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1
- Registration Number
- NCT06094296
- Locations
- 🇺🇸
Local Institution - 0058, Boise, Idaho, United States
🇺🇸Local Institution - 0044, Clermont, Florida, United States
🇺🇸Local Institution - 0049, Houston, Texas, United States
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06085729
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Safety of KAND567, in Combination with Carboplatin Therapy, in Women with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Kancera AB
- Target Recruit Count
- 18
- Registration Number
- NCT06087289
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
🇳🇴Oslo University Hospital, Oslo, Norway
🇸🇪Skåne University Hospital, Lund, Sweden
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
- Conditions
- Oropharyngeal Squamous Cell CarcinomaStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8Stage III Lip and Oral Cavity Cancer AJCC v8Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8Head and Neck Squamous Cell CarcinomaLaryngeal Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaStage IV Laryngeal Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionDrug: CarboplatinProcedure: Chest RadiographyDrug: CisplatinProcedure: Computed TomographyRadiation: Image Guided Radiation TherapyRadiation: Intensity-Modulated Radiation TherapyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyDrug: Xevinapant
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Registration Number
- NCT06084845
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT06077500
- Locations
- 🇪🇸
Hospital Virgen Macarena, Sevilla, Spain
🇧🇪Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk, Belgium
🇫🇷INS Bergonie, Bordeaux, France
Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT06066216
PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
- Conditions
- Interventions
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Presage Biosciences
- Target Recruit Count
- 15
- Registration Number
- NCT06062602
- Locations
- 🇺🇸
LSU Health Sciences Center - Shreveport, Shreveport, Louisiana, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Cincinnati Health, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.